The findings presented in this study, although preliminary, provide new evidence to suggest that MYCN amplification leads to antifolate sensitivity, and that methotrexate may be beneficial in a subset of patients with MYCN-amplified neuroblastoma and high SLC19A1 expression. This evidence concerns the gene SLC19A1 and neuroblastoma.